# Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease

Study · id `cardio:ct-nct06350123` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06350123](<https://clinicaltrials.gov/study/NCT06350123>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06350123

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 324 participants.

## Technical summary

Registry record NCT06350123. Randomized; quadruple masking; primary purpose treatment. Start 2024-05-01 (actual); primary completion 2025-05-09 (actual). Results posted on 2026-06-26.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 324 participants (enrolled count; ClinicalTrials.gov record NCT06350123, source copy `cardio:ctgov-nct06350123-2026-06-26`, retrieved 2026-10-31)
- Started: 2024-05-01 (actual) (ClinicalTrials.gov record NCT06350123, source copy `cardio:ctgov-nct06350123-2026-06-26`, retrieved 2026-10-31)
- Primary completion: 2025-05-09 (actual) (ClinicalTrials.gov record NCT06350123, source copy `cardio:ctgov-nct06350123-2026-06-26`, retrieved 2026-10-31)
- Completion: 2025-05-09 (actual) (ClinicalTrials.gov record NCT06350123, source copy `cardio:ctgov-nct06350123-2026-06-26`, retrieved 2026-10-31)
- Results first posted: 2026-06-26 (ClinicalTrials.gov record NCT06350123, source copy `cardio:ctgov-nct06350123-2026-06-26`, retrieved 2026-10-31)
- Countries: United States; Austria; Brazil; Bulgaria; Canada; China; Italy; Japan; Malaysia; Poland; Spain; Taiwan; Türkiye; United Kingdom; Vietnam (ClinicalTrials.gov record NCT06350123, source copy `cardio:ctgov-nct06350123-2026-06-26`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06350123-2026-06-26`, retrieved 2026-10-31)

## The registry's words

- Brief title: Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease
- Acronym: MIRO-CKD
- Condition: Chronic Kidney Disease
- Intervention (Drug): Balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg
- Intervention (Drug): Balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg
- Intervention (Drug): Dapagliflozin 10 mg and matching placebo for balcinrenone/dapa gliflozin
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Balcinrenone in combination with dapagliflozin compared with dapagliflozin alone in patients with chronic kidney disease and albuminuria: a randomised, active-controlled double-blind, phase 2b clinical trial (`cardio:pubmed-41218621`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 15174b5fd0ff776c6d10b76886432c48f81ee3b3776d5779c099a4edd0173aa3
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
